StockGuru Blog: RxElite (SOUT) Anticipates 11% to 15% of the Sevoflurane Market as One of Three Distributors!
Stock Guru Profile News Blogs I think we are going to see a dramatic uptick in earnings with SOUT. The Sevoflurane market in the U.S. is at conservative estimates $350M. In the Oppenheimer Report RxElite delivered a forecast of 11%-15% yr-yr market growth: that is $38.5M to $52.5M in market growth for RxElite. The recent Oppenheimer Reports which focus on Rx Elite’s distribution agreement for sevoflurane in the United States for Minrad International paint an excellent portrait of the opportunities here. Today we examine the June 28, 2007, Oppenheimer Report In a nutshell: Initial rollout on track to ahead of…